Our study population consisted of patients with advanced-stage (stage IV in 46 out of 48 patients) adenocarcinoma with sensitizing EGFR mutations and all of them were treated with EGFR TKI as their first-line systemic therapy. The gene discussed is EGFR; the disease is adenocarcinoma.